Earnings Growth Forecast for Divi’s Laboratories Ltd
Divi’s Laboratories Ltd is anticipated to report robust double-digit year-on-year (YoY) growth in earnings for the quarter ending December. This growth is expected to be driven by a favorable base and stable raw material costs.
- Consolidated Net Profit: Expected to rise by 33% YoY to Rs 407.40 crore.
- Revenue: Likely to grow by 17% YoY to Rs 1,994.20 crore.
- Operating Profit (EBITDA): Estimated to increase by 38% to Rs 562 crore.
Divi’s Laboratories Ltd, headquartered in Hyderabad, is scheduled to announce its quarterly earnings on Saturday.
₹160 Dividend Share; This Company announced interim dividend of ₹100.00 and a special dividend of ₹60.00 per equity share
About DIVISLAB
Divi’s Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Hyderabad. Founded by Murali Divi on October 12, 1990, the company specializes in the production of active pharmaceutical ingredients (APIs) and intermediates. Divi’s Laboratories manufactures and custom synthesizes generic APIs and intermediates.
Kiran S. Divi has been serving as the CEO since January 2020. As of 2023, the company has a workforce of 8,433 employees. In terms of revenue, the company generated 9,073 crores INR (approximately US$1.1 billion) in 2022. Divi’s Laboratories operates through subsidiaries such as Divi’s Laboratories Europe AG and Divis Laboratories (USA), Inc.
Tata Group Share Q3 Results; 100% Return: Down 64.96% to a net profit of Rs 527.8 crore
Divi’s Laboratories Ltd Fundamental
Divi’s Laboratories Ltd showcases several fundamental metrics. Its market capitalization stands at ₹96,957.09 Cr., while the enterprise value amounts to ₹92,769.53 Cr. The company has 26.55 Cr. shares outstanding, with a price-to-earnings (P/E) ratio of 73.64 and a price-to-book (P/B) ratio of 7.7. The face value of its shares is ₹2, and it offers a dividend yield of 0.82%. The trailing twelve-month (TTM) book value is ₹474.52, and it holds ₹4,187.56 Cr. in cash with no debt.
Promoter holding is at 51.92%. The earnings per share (EPS) TTM is ₹49.60, and it has seen a sales growth rate of -14.13%. Return on equity (ROE) stands at 14.82%, and return on capital employed (ROCE) at 19.31%. However, the company has witnessed a decline in profit growth, recording -38.68%.
42% Return This Share; Sachin Tendulkar’s Company becomes Rolls-Royce partner
Conclusion
This article is a comprehensive guide to the Divi Labs Q3 Result Declare; Net profit increase by 33%, 407.40 crore Profit. The information and forecasts are derived from our analysis, research, company fundamentals, historical data, experiences, and various technical analyses. The article delves into the share’s prospects and growth potential in detail. Feel free to comment below if you have any further queries. We are more than happy to address all your questions. If you find this information helpful, consider sharing the article with as many people as possible.
Disclaimer:
Dear readers, please be advised that we are not authorized by SEBI (Securities and Exchange Board of India). The information provided on this site is solely for informational and educational purposes and should not be construed as financial advice or stock recommendations. Additionally, share price predictions are intended for reference purposes only and are valid only under positive market conditions.
This study does not consider any uncertainties regarding the company’s future or the current market conditions. While this information is for informational purposes, we disclaim any responsibility for potential financial losses incurred based on the information provided on this site. We aim to offer timely updates about the stock market and financial products to assist you in making informed investment decisions. It is crucial to conduct your research before making any investment decisions.
